Cold Plasma Market Trends

Cold Plasma Market Trends

Cold plasma is being explored for its potential in cancer treatment, particularly in oncology which is estimated to reach USD 690.4 billion by 2032. It is used to selectively target and kill cancer cells without harming healthy tissue. For instance, the Jerome Canady Research Institute (JCRI) and US Medical Innovations (USMI) have achieved success in an FDA Phase 1 Clinical Trial by using Canady Helios Cold Plasma (CHCP) alongside tumor resection. This approach selectively eliminates cancer cells at the surgical margin without harming healthy tissue, resulting in reduced local recurrence, improved overall survival, and the potential eradication of post-surgery residual cancer cells.
 

• Furthermore, continual research and technological advancements have enhanced the efficiency and versatility of cold plasma. Developments in equipment, processes, and precision control have improved its practicality and effectiveness in various applications.
   
• Therefore, these advancements, such as portable devices and a better understanding of material interactions, are fueling the adoption of cold plasma across multiple industries, with healthcare benefiting significantly.